Full Breakdown
Trump Administration Unveils New Drug Pricing Initiatives for Medicaid and Medicare
11/7/2025, 10:47:48 PM
Introduction of the GENEROUS Model
On November 6, 2025, the Trump administration announced the introduction of the Generating Cost Reductions for U.S. Medicaid (GENEROUS) Model, a new initiative aimed at reducing prescription drug costs for Medicaid patients. This program will allow participating state Medicaid programs to purchase drugs at prices aligned with those in other developed countries, including the United Kingdom, France, Germany, Italy, Canada, Japan, Denmark, and Switzerland. The initiative is part of a broader strategy to implement "most favored nation" pricing, which ties U.S. drug prices to lower prices abroad.
Key Features of the GENEROUS Model
The GENEROUS Model will launch in January 2026 and run for five years, allowing states to negotiate with drug manufacturers for lower prices. States that opt into the program will implement uniform coverage criteria for Medicaid beneficiaries. The Centers for Medicare and Medicaid Services (CMS) reported that total Medicaid spending on prescription drugs exceeded $100 billion in 2024, highlighting the need for reform. The model is voluntary for both states and manufacturers, with no minimum participation required.
Expansion of Medicare Coverage for Weight-Loss Drugs
In conjunction with the GENEROUS Model, President Trump announced agreements with pharmaceutical companies Eli Lilly and Novo Nordisk to lower prices for GLP-1 weight-loss drugs, including Wegovy and Zepbound. Starting in mid-2026, Medicare will cover these medications for patients with a body mass index (BMI) over 35, as well as those with other qualifying health conditions. Medicare beneficiaries will pay a co-pay of $50 per month, while the average price for these drugs will start at $350 and trend down to $245 over two years.
Implications for Patients and States
The new pricing agreements are expected to significantly expand access to these medications for millions of Americans. Approximately 10% of the Medicare population is estimated to qualify for expanded access under the new guidelines. The initiative aims to address the high costs of obesity medications, which have historically been out of reach for many patients. Currently, many private insurers do not cover these drugs for weight loss, although they may cover them for other health conditions.
Criticism and Concerns
Despite the potential benefits, experts have raised concerns about the clarity and accessibility of the new pricing structure. Some have questioned how many patients will actually benefit from the changes, given that many existing Medicare plans may not participate in the program. Additionally, there are uncertainties regarding how states will manage their Medicaid programs under the new model, particularly in light of budgetary constraints.
Official Statements
CMS Administrator Dr. Mehmet Oz stated, “Under the leadership of President Trump and Secretary Kennedy, CMS is making a historic commitment to driving down the cost of drug prices and ensuring Americans have access to life-saving medications.” Health and Human Services Secretary Robert F. Kennedy Jr. emphasized the significance of the agreements, claiming they would have "dramatic effects on human health" in the U.S.
Verbatim Quotes
- “This is going to have the biggest impact on the American people.” — Robert F. Kennedy Jr., Secretary of Health and Human Services
- “Drug prices in the US remain far too high,” — Abe Sutton, CMS Innovation Center Director
- “Thanks to President Trump’s leadership and Dr. Oz’s bold direction at CMS, we’re expanding access to affordable medicines for millions of Americans,” — Robert F. Kennedy Jr.
Conclusion and Future Outlook
The GENEROUS Model and the new agreements with Eli Lilly and Novo Nordisk represent significant steps in the Trump administration's efforts to lower drug prices and expand access to essential medications. As the program rolls out, the impact on Medicaid and Medicare beneficiaries will be closely monitored, with the potential for broader implications across the healthcare system. The administration plans to release further details and guidelines for state participation in the coming months.
